

220 health partnerships

Disease focus

20%
focus on HIV/AIDS




16%
focus on Neglected Tropical Diseases

16%
focus on Women and Children's Health



14%
focus on Malaria

14%
focus on Non-Communicable Diseases

1 of 2 programs focus on strengthening health system infrastructures



Types of partners (% of total partnerships)



Region	Count	Example Countries
Sub-Saharan Africa	146	(Tanzania 77)
East Asia and Pacific	80	(Cambodia 38)
South Asia	76	(India 55)
Latin America and Caribbean	71	(Brazil 34)
Middle East and North Africa	39	(Egypt 20)
Europe and Central Asia	38	(Uzbekistan 21)
North America	9	(USA 9)

Geographic focus

High presence (> 50% of partnerships) | Medium presence (26%-50% of partnerships) | Low presence (0-25% of partnerships)

Top 10 recipient countries

1. Tanzania	77
2. Kenya	69
3. Uganda	62
4. India	55
5. South Africa	49
6. Senegal	46
7. Ghana	45
8. Nigeria	45
9. Mozambique	43
10. Ethiopia	43

Technology transfer

51 programs active since 2005

40 recipient countries (top: China, India, Thailand)

7 types of partners involved

1 of 2 programs involve a BRIC country

1/3 of programs are in Africa

1985 first program

NTD focus

132 R&D projects to develop new medicines and vaccines

85% of these projects are carried out through collaborative approaches

3rd we are the 3rd largest global funder of R&D for NTDs

525.1 our investments in NTD research reached USD 525.1 million in 2011

7 R&D centers are dedicated solely to searching for new cures for NTDs

32 access to capacity building partnerships devoted to NTDs

14 billion treatments donated from 2011 to 2020

Challenges

In low- and middle-income countries, achieving global health goals is a slow process. The challenge is often attributed to systemic issues such as:

- 1 Inadequate health system infrastructures (a trained health workforce, operating health information systems, and adequate physical facilities)
- 2 Limited availability (or absence of) of treatment
- 3 Inadequate R&D focused on key global health issues and insufficient in-country capacity for R&D
- 4 Limited health awareness and outreach to support prevention and care



International Federation
of Pharmaceutical
Manufacturers & Associations